SUMMARY
INTRODUCTION

Tuberculosis (TB) is a chronic infectious disease caused by
Mycobacterium tuberculosis that continues to be among the top five causes of death in 18 countries (GBD 2013 Mortality and Causes of Death Collaborators, 2015) . Increased prevention would be a tremendous asset in controlling the global epidemic, as reflected by World Health Organization's new End TB Strategy (Uplekar et al., 2015) . Rational design of an improved vaccine that is able to prevent active disease would be the most effective measure in TB control (Knight et al., 2014) . Thus, numerous efforts are being undertaken to develop improved anti-TB vaccines, some of which have recently entered clinical development (Fletcher et al., 2016; Grode et al., 2013; Spertini et al., 2015) .
The currently licensed anti-TB vaccine Mycobacterium bovis BCG, also known as Bacille Calmette Gué rin, confers insufficient protection against pulmonary TB in adolescents and adults . The absence of a 9.5-kb genomic region across all BCG strains, termed Region of Difference 1 (RD1), is the principal molecular determinant underlying BCG attenuation (Hsu et al., 2003; Pym et al., 2002) . RD1 harbors genes required for the paradigm type VII secretion (T7S) ESX-1, or ESAT-6 secretion system that is dedicated to the export of proteins that play key roles in host-pathogen interactions and pathogenic potential . During infection of host phagocytes, a functional ESX-1 secretion system and selected lipids (i.e., phthiocerol dimycocerosates) are required for communication of M. tuberculosis with the host cytosol Augenstreich et al., 2017) , with subsequent detection of bacterial DNA by cytosolic sensors, and mitochondrial stress (Wiens and Ernst, 2016) . This process leads to a cascade of innate immune signaling events (Collins et al., 2015; Wassermann et al., 2015; Watson et al., 2015) , including reinforced AIM-2 (Absence in Melanoma 2) and NLRP3 inflammasome activation, increased interleukin-1b (IL-1b) and/or IL-18 secretion (Dorhoi et al., 2012; Kupz et al., 2016; Wong and Jacobs, 2011) and activation of the cyclic GMP-AMP synthase (cGas)/Stimulator of Interferon Genes (STING)/TANK-binding kinase 1 (TBK1)/IRF3 axis. The latter signaling cascade results in the production of type I interferons (IFNs) (Stanley et al., 2007) . Apart from innate immune activation, secreted ESX-1 effectors also induce specific host Th1 cell (Bange et al., 1999) , the NheI cloning site, and the 38.7-kb insert from M. marinum M containing the esx-1 locus. Amino acid sequence identities between gene products in the orthologous esx-1 loci of M. marinum and M. tuberculosis are depicted in percentages. (B) PCR-based verification of the integration of the esx-1 locus into BCG::ESX-1 Mmar , using several primers spanning the esx-1 locus of M. marinum and negative and positive DNA controls. (C) Ethidium-bromid stained fragments of XhoI restriction digest of pRD1-Mmar, separated by agarose gel electrophoresis.
(legend continued on next page)
responses with strong protective potential (Brodin et al., 2004 (Brodin et al., , 2006 . Early attempts to improve the protective efficacy of BCG by heterologously expressing ESX-1 from M. tuberculosis, a biosafety level (BSL) 3 organism, produced mixed results. Vaccine efficacy was improved (Pym et al., 2003) , but as a side effect virulence was increased (Pym et al., 2002) , making this recombinant BCG strain likely too virulent as to be used for vaccine applications. Thus, the rationale emerged to express the ESX-1 systems of related but less pathogenic mycobacteria in BCG. M. tuberculosis H37Rv and M. marinum, a BSL2 aquatic mycobacterium that can infect fish or frogs and occasionally causes skin infections in humans, share a substantial core genome, with high amino acid sequence conservation, particularly across the genes encoding the ESX-1 system ( Figure 1A) . Here, we engineered a recombinant BCG candidate vaccine that harbored the esx-1 locus of M. marinum (BCG::ESX-1
Mmar
). We then interrogated the biological and immunological consequences of this heterologous ESX-1
Mmar expression in the context of vaccination. Using different murine infection models, we identified previously undiscovered immunological features of recombinant BCG linked to cytosolic pattern recognition and we provide compelling evidence of significantly improved protective vaccine efficacy.
RESULTS
Construction of the Recombinant BCG ESX-1
Mmar -Proficient Strain An esx-1 locus-containing clone was selected from a Bacterial Artificial Chromosome (BAC) library of M. marinum reference strain M. This library was originally constructed to scaffold and validate the whole-genome sequence assembly of this strain (Stinear et al., 2008) . The BAC clone was used as substrate for sub-cloning a 38.7-kb-sized fragment into the integrating cosmid vector pYUB412 (Bange et al., 1999) (Figures 1A and 1B) . Sequence analysis revealed that the cloned fragment carried a nucleotide deletion in the eccCb 1 gene (6 C instead of 7 C in the published genome sequence [Stinear et al., 2008 ] GenBank CP000854 at position 6589,378-84) ( Figure S1 ), causing a frameshift in EccCb 1 . Further analysis showed that the same eccCb 1 nucleotide deletion was present in the genome of the M strain (M Pasteur ), used for construction of the BAC library ( Figure S1 ).
This finding likely explains the previously reported differences in ESAT-6 secretion and virulence between the attenuated M. marinum M VU variant and other M. marinum M variants used in diverse laboratories (Abdallah et al., 2009; Hagedorn et al., 2009; Ramakrishnan et al., 2000; Simeone et al., 2012) , as the M. marinum M VU also harbors this mutation. The frameshift in the cosmid was repaired using a phage lambda Red recombineering approach (Chaveroche et al., 2000) . We then transformed the ESX-1-repaired cosmid into BCG Pasteur 1173P2 ( Figure 1C) . Comparison of the in vitro growth characteristics of the obtained recombinant BCG::ESX-1
Mmar strain showed that they were similar to other BCG strains ( Figure S2A ).
The Heterologous ESX-1 System Is Functional in the BCG::ESX-1
Mmar
The main secreted M. tuberculosis ESX-1 effectors ESAT-6 and CFP-10 share very high amino acid sequence identity with their M. marinum orthologs ( Figure S2B ), so we assessed the functionality of the heterologous ESX-1
Mmar secretion machinery by using major histocompatibility complex (MHC)-II-restricted T cell hybridomas specific to different ESX-1 effectors. In this model, presentation of ESX-1 effectors is dependent on their proper secretion (Frigui et al., 2008 Figure 1D ). Similarly, EspC (Rv3615c), an ESX-1-secretion-associated protein that forms secretion-needle-like structures (Ates and Brosch, 2017; Lou et al., 2017) , and is exported in a co-dependent way with ESAT-6 (MacGurn et al., 2005) , was efficiently presented by BM-DCs infected with either BCG::ESX-1 Mmar and BCG::ESX-1 Mtb ( Figure 1D ). All tested BCG strains induced the antigenic presentation of the control antigen Ag85A, secreted by the Twin-Arginine Translocation (TAT) pathway ( Figure 1D ). (Pym et al., 2002 (Pym et al., , 2003 . M. tuberculosis H37Rv). This effect was evaluated by the upregulation of the CD40, CD80, and CD86 co-stimulatory molecules, modulation of MHC-I/II expression ( Figure S3A of pro/anti-inflammatory cytokines and chemokines ( Figure S3B ). As selected ESX-1-proficient mycobacteria such as M. marinum, M. kansasii, or M. tuberculosis Stamm et al., 2003; Wang et al., 2015) have been shown to induce ESX-1-mediated phagosome-to-cytosol communication, we explored whether BCG::ESX-1
Mmar was able to induce phagosomal rupture in host phagocytes. We used a flow-cytometric fluorescence resonance energy transfer (FRET) approach based on a green-to-blue fluorescence shift following cleavage of cytosolic coumarin-cephalosporin-fluorescein 4 (CCF4) by endogenous mycobacterial b-lactamase . Analysis of infected human THP-1 macrophages revealed that BCG::ESX-1 Mmar induced a solid blue shift, implying contact with the host cytosol, albeit to a lesser degree compared to M. tuberculosis H37Rv and BCG::ESX-1 Mtb ( Figure 3A ). In contrast, the ESX-1-deficient negative control BCG strain did not induce a blue shift in the infected cells ( Figure 3A) . Figure 3C ). As a functional control, we showed that cGAS or STING-deficient THP-1 cells released tumor necrosis factor-a (TNF-a)-like WT ( Figure 3C ). These data support our contention that a type I IFN response by ESX-1-proficient BCG strains depends on cytosolic exposure of mycobacterial DNA to then associate with cGAS.
In parallel, we found that infection with BCG::ESX-1
Mtb or WT M. tuberculosis, significantly enhanced release of active IL-1b, compared to BCG::pYUB and M. tuberculosis DESX-1 ( Figure 3B ). These data are in agreement with earlier studies, which revealed that the release of active IL-1b is partially dependent on the interaction of mycobacterial DNA with AIM2 (Saiga et al., 2015) . Since ESX-1-dependent activation of STING has been reported to increase autophagy (Watson et al., 2012) , we tested whether the BCG::ESX-1 Mmar or BCG::ESX-1 Mtb increased the presence of the cytosolic autophagy effector microtubule-associated protein 1A/1B-light chain 3 (LC3)-II. Using a flow-cytometry-based assay, we observed increased LC3-II accumulation in THP-1 cells infected with ESX-1-proficient recombinant BCGs relative to BCG::pYUB-infected cells ( Figure S4A ), without notable differences in cell mortality ( Figure S4B ). However, the observed differences between BCG WT and recombinant strains remained relatively small, in concordance with previous studies using western blotting or confocal microscopy (Romagnoli et al., 2012; Watson et al., 2012) 
-immunized mice also displayed IFN-g T cell responses against non-ESX-1-associated antigens shared with BCG that were comparable to those induced by the BCG::pYUB control, as exemplified by Ag85A-, PE19-, or PPE25-specific IFN-g release ( Figure S5A ).
In-depth characterization of the functional Th1 subsets by intracellular cytokine staining (ICS) (Figures 4A, S6 , and S7) showed (Behar, 2013; Ryan et al., 2009) . To evaluate the impact of BCG complementation with ESX-1, we immunized C3H (H-2 k ) mice that specifically recognize a MHC-I-restricted CFP-10:32-39 epitope (Kamath et al., 2004) and found that the mice mounted CD8 + T cell responses against CFP-10, as detected by IFN-g production subsequent to stimulation of splenocytes with the peptide ( Figure 5A ). In addition, higher percentages of TNF-a + IFN-g Figure 7B ) and M. tuberculosis strain M2 from the Harleem family ( Figure 7C ), as evidenced by greatly reduced mycobacterial loads in the lungs and spleen, as well as decreased proportions of inflamed lung tissue ( Figure 7D ).
DISCUSSION
With millions of doses delivered across generations of humans around the world, BCG is perhaps the most well-known example of a live, attenuated vaccine and is still widely used today as no higher-performing alternatives have been licensed to date. Developed in the 1920s by Calmette and Gué rin after longterm in vitro passaging of a virulent Mycobacterium bovis isolate that became irreversibly attenuated, vaccination with BCG of an estimated 3 billion individuals confirmed that BCG was safe in the immunocompetent host (Fine et al., 1999) . Besides BCG, the other human anti-TB vaccine used at a larger scale is the vole-bacillus Mycobacterium microti. Different attenuated variants were successfully used to vaccinate 10,000 adolescents in the UK (Hart and Sutherland, 1977) and half a million babies in the former Czechoslovakia (Sula and Radkovský , 1976) in the 1960s. However, reflection on the history of almost 100 years of human anti-TB vaccination shows that despite undeniable beneficial effects conferred to small children, vaccination with BCG or M. microti has been insufficient to prevent the current global reemergence of TB. Interestingly, BCG and M. microti strains have one major genetic feature in common. They have independently deleted portions of the region of difference 1 (RD1) (Mahairas et al., 1996; Brodin et al., 2002) , which in M. tuberculosis and many other mycobacteria encodes the ESX-1 type VII secretion system (Abdallah et al., 2007; Bottai et al., 2016; Grö schel et al., 2016) . The biological basis for key ESX-1-mediated effects are primarily linked to the ESX-1-dependent induction of phagosome-cytosol communication van der Wel et al., 2007; Conrad et al., 2017) . Indeed, mycobacterial cytosolic contact triggers a cascade of cellular signaling events that are of upmost importance for innate and adaptive immune responses. ESX-1-deficient BCG and M. microti vaccine strains are unable to initiate these responses .
We reasoned that influencing phagosome biology through ESX-1 secretion might enhance the protective ability of BCG, and we wanted to uncouple the beneficial immunological ESX-1-mediated effects from the gain-of-virulence linked to the insertion of genes from a BSL3 organism into BCG. We thus heterologously expressed in BCG the ESX-1 from M. marinum, a mycobacterium that shares with BCG the BSL2 classification. Successful integration of the M. marinum ESX- gests that phagosome escape is not the only determining factor that explains the virulence differences observed between ESX-1-proficient and ESX-1-deficient mycobacteria. Alternatively, the heterologous expression of a large DNA fragment from a more distantly related species with different host specificity, i.e., M. marinum, in BCG might reduce the in vivo fitness of the recombinant BCG::ESX-1
Mmar
, although we observed similar in vitro growth characteristics to standard BCG.
We next evaluated the immunological repercussions of the ESX-1-introduction into BCG by analyzing innate immune responses, particularly in light of the most recent literature. IL-1b is protective in the context of M. tuberculosis infection (Fremond et al., 2007) , and its catalytic cleavage is mediated by the NLRP3 inflammasome/caspase-1 pathway (Muruve et al., 2008) . We showed that ESX-1-proficient BCGs mount a higher IL-1b response suggesting that cytosolic access of mycobacterial compounds promotes activation of the inflammasome. In addition to induction of IL-1 b, recent evidence points to a role for ESX-1-mediated cytosolic contact in NLRP3-inflammasomemediated secretion of IL-18 by infected CD11c + immune cells (Kupz et al., 2016) . This leads to non-cognate production of IFN-g by M. tuberculosis-antigen-independent memory CD8 + T cells and NK cells. Such IL-18-dependent and rapid IFN-g responses are not induced by current anti-TB vaccines (Gengenbacher et al., 2016; Kupz et al., 2016) . In this context, the rationale is strengthened for leveraging ESX-1 function as an important additional element in the design of third-generation vaccines and host-directed therapy against TB.
By acquiring cytosolic access, mycobacterial molecular fingerprints, such as extracellular DNA, can also be sensed by germline-encoded pattern recognition receptors in host cell such as AIM2 (Hornung et al., 2009; Saiga et al., 2015) or cGAS (Collins et al., 2015; Wassermann et al., 2015; Watson et al., 2015) . We observed that the BCG::ESX-1 strains induced IFN-b mediated by the cGAS/STING pathway in human macrophages. We acknowledge that the role of type I IFNs in the context of M. tuberculosis infection is somewhat conflicted (McNab et al., 2015) . Studies in humans (Berry et al., 2010) and in animal models report a detrimental role of type I IFNs during M. tuberculosis infection (Manca et al., 2005; Ordway et al., 2007; Stanley et al., 2007) . A possible explanation is that IFN-a/b undermine inflammasome activation and associated host protective cytokines such as IL-1b (Guarda et al., 2011) . However, this pro-bacterial role of type I IFNs during infection with M. tuberculosis could turn out to be pro-host during vaccination. While type I IFNs negatively regulate active IL-1b secretion during M. tuberculosis infection (Novikov et al., 2011) , we observed both increased IL-1b and IFN-b production induced by the ESX-1-proficient BCG vaccine candidates. Therefore, if an activated cGas/STING/TBK1/IFR3/ type I IFN pathway contributes to the persistence of attenuated vaccine strains and the activation of non-infected neighboring cells (Ablasser et al., 2013) , this effect might favorably increase the spatial and temporal interplay between the vaccine and the host immune system, ultimately contributing to improved vaccine efficacy.
Apart from the prompt innate immune response, the late adaptive immune system plays a key role in anti-mycobacterial immunity (Orme et al., 2015) . We found that the BCG:: ESX-1
Mmar induces a potent Th1 cell response against strong immunogens exported by ESX-1, which enlarges the antigenic repertoire compared to the currently used BCG vaccine, and thus represents a desirable feature in the light of the incomplete protection conferred by BCG. The presence of polyfunctional with z150 CFUs/mouse of M. tuberculosis H37Rv strain via aerosol route, as determined by CFU counting in the lungs day 1 post-infection. The mycobacterial loads in the lungs (B) and spleen (C) of individual mice were determined. NS, not significant, *, **, ***, ****, statistically significant, as determined by one-way ANOVA test with Tukey's correction, with p < 0.05, p < 0.005, p < 0.001, or p < 0.0001, respectively. Note that for these experiments a H37Rv M. tuberculosis strain was used that was passaged in the past in mice to maintain high virulence, and that the inoculum for the aerosol challenge was prepared from exponentially growing cultures. The CFUs in the lungs and spleens of each group were analyzed by culturing lung and spleen homogenates and enumerating the bacteria. Note that CFU data shown correspond to counts that were obtained from the left-superior lobes of the lungs. The data are presented as the median ± interquartile range (IQR) log 10 CFUs/organ (n = 6), and the levels of significance for comparisons between samples were determined by a one-way ANOVA, followed by Dunnett's multiple comparison test.
(legend continued on next page)
Th1 cytokine-producing cells against ESX-1-secreted antigens upon vaccination with the recombinant BCGs adds another convincing feature of the broadened T cell specificities. Apart from CD4
+ T cells, we detected improved CD8 + T cell responses by analyzing functional CD8 + T cells. This strong adaptive immune response could be partly explained by a bridging function of activated IFN-b between innate and adaptive immunity, as has been described for type I IFNs (Le Bon et al., 2003) . Importantly, in addition to type I IFNs IL-1b and inflammasome activation also play roles in regulating the differentiation and function of CD8 + T cells during M. tuberculosis infection (Booty et al., 2016) . CD8 + T cell effectors are primed through increased inflammasome signaling (IL-1b), in concert with the upregulation of chemo-attractants CCL2, CCL5, and CXCL10, of which we detected elevated levels ( Figure S3B ) (Le Bon et al., 2003; Sagoo et al., 2016) . These data support a model where ESX-1-mediated cytosolic access assists presentation to and activation of the cytosolic presentation machinery through induction of type I IFNs (Le Bon et al., 2003) and potentially increased bacterial persistence (Woodworth et al., 2008) . The hypothesis that ESX-1-mediated cytosolic access improves the performance of recombinant BCG through enhanced innate immune signaling and enlarged antigenic repertoire is supported by our results from the mouse models where BCG:: ESX-1
Mmar showed superior protective efficacy compared to parental BCG. These results are in accord with those obtained using an attenuated M. tuberculosis strain that lacks the characteristic esx-5-associated pe/ppe genes, but harbors all other components of the ESX-5 system, as well as an intact ESX-1 system (Sayes et al., 2012) . Like BCG::ESX-1
Mmar
, this strain named MtbDppe25-pe19 is able to induce innate immune responses linked to cytosolic pattern recognition and shows significantly improved protection against an M. tuberculosis challenge in a mouse infection model . These results suggest that, despite the different genetic background and the different origin of the ESX-1 system, ESX-1-mediated functions are essential for increasing protection levels above those provided by vaccination with standard BCG strains.
In conclusion, the heterologous expression of an M. marinumderived ESX-1 system in BCG yielded a recombinant vaccine candidate with relatively low virulence levels in SCID mice, which are comparable with those of other BCG strains (Zhang et al., 2016) , and a capacity to induce selected innate and adaptive immune responses that depend on phagosome-cytosol communication in the host phagocyte. Such responses are not induced by first-generation anti-TB vaccines such as BCG or M. microti and might as well not be induced by the second-generation anti-TB vaccine candidates that have recently entered clinical development (Kupz et al., 2016) . Given that 90%-95% of M. tuberculosis exposed individuals do not develop active TB disease during their lifetime, host immune effectors are largely capable of inducing protective immunity (Ottenhoff and Kaufmann, 2012) . We propose that a virulence-attenuated, ESX-1-proficient BCG vaccine might be best able to mimic the natural route of infection and induce the ''correct'' phagosomal biology, leading to protective immunity at the same points of host-pathogen contact as M. tuberculosis. We argue that this important biological feature should not be left out from the rational design of third-generation vaccines, giving BCG::ESX-1
Mmar a clear potential to better control TB.
EXPERIMENTAL PROCEDURES Mycobacterial Strains and Preparation of Recombinant Strains
Mycobacterial strains included the M. tuberculosis strains H37Rv (stocks held at Institut Pasteur, Paris), HN878 and M2 (ITRC, Changwon), as well as the BCG strains Pasteur 1173P2 and Danish 1331. Recombinant strains were obtained by transformation with the pRD1-2F9 cosmid (Pym et al., 2002 ) and the pESX-1 Mmar cosmid described in detail in the Supplemental Information.
Antigen-Presenting Assay
Several MHC-II-restricted T cell hybridomas specific to mycobacterial antigens were used in order to detect the secretion by mycobacteria, which leads to the antigenic presentation by the infected BM-DCs of different ESX-1 substrates, as described in detail in the Supplemental Information.
ELISA and Multiplex Cytokine and Chemokine Assays and FRET Assays Levels of various cytokines and chemokines in BM-DC culture supernatants were determined by multiple ProcartaPlex (Affymetrix) kit assays and a Luminex X-100 Reader (Supplemental Information). For FRET analyses a recently described protocol was used with THP-1 cells to detect fluorescence emission changes from green (535 nm) to blue (447 nm) induced by b-lactamase-mediated cleavage of coumarin-cephalosporin-fluorescein (CCF-4) (Supplemental Information).
Immunogenicity and T Cell Assay and T Cell Intracellular Th1
Cytokine Assay For immunological studies splenocytes from immunized C3H and C57BL/6 mice (Janvier) were cultured in 24-or 96-well plates in the presence of various mycobacterial antigens, followed by ELISA-mediated quantification of IFN-g and/or flow-cytometric analysis (described in detail in the Supplemental Information). 
In Vivo Experiments
Statistical Analyses
For statistical analyses, GraphPad Prism software (GraphPad) was used as described in detail in the Supplemental Information.
(D) Lung samples collected for histopathology were preserved overnight in 10% normal buffered formalin, embedded with paraffin, sliced into 4-to 5-mm-thick sections, and stained with H&E. The superior lobes of the right lung were stained with H&E to assess the severity of inflammation. The level of inflammation in the lungs was evaluated using ImageJ software (NIH). Percentages of the inflamed areas are presented as whisker boxplots (whiskers represent minimum and maximum values) (n = 6), and a one-way ANOVA followed by Dunnett's test was used to determine the significance of the findings.
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The accession number for selected flow-cytometric data reported in this paper is Flow Repository: FR-FCM-ZY24 (https://flowrepository.org/id/FR-FCM-ZY24). 
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